Supplementary table 1. The target value range of each mutant of the quality control. Supplementary table 2. The judging rule of the KRAS mutant gene. Supplementary table 3. Detection of the mutKRAS ctDNA in all enrolled patients.

Supplementary table 1. The target value range of each mutant of the quality controlSupplementary table 2. The judging rule of the KRAS mutant gene.Supplementary table 3. Detection of the mutKRAS ctDNA in all enrolled patients.<br>Background: The prognosis of resectable pancreatic cancer (PC) patients with the same stage of disease is highly variable. The purpose of this study is to establish a scoring system for preoperative screening of resectable patients. Methods: The clinical information and laboratory tests of 105 resectable patients with PC were enrolled and analysed. Results: The consistency of clinical stage and pathological stage was poor (κ = 0.193, P &lt; 0.003). We performed a comprehensive scoring system with KRAS mutations in circulating tumor DNA (mutKRAS ctDNA) for the resectable patients. Patients with higher scores were more prone to early postoperative recurrence and poorer prognosis. Conclusions: The scoring system can help preoperatively screen out resectable patients who are prone to early postoperative recurrence.<br>